Geron’s resurgence might have been short-lived
Geron Corporation, which has largely toiled in obscurity since the 1990s, rocketed back to relevance with news that its treatment for a group of chronic blood disorders succeeded in a late-stage…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, everyone. Damian here with a look at why some wished-for gene therapies failed to make a splash when they came true and the words of ALS patients in the aftermath of another crushing setback.
What's Your Reaction?
